Latest Breaking News On - Esophageal diseases - Page 1 : comparemela.com

Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

Eohilia Gets FDA Approval for Swallowing Disorder Eosinophilic Esophagitis

Eohilia is the first FDA-approved treatment specifically for eosinophilic esophagitis, a rare inflammatory disease of the esophagus.

Dupilumab for EoE: How Is it Improving Treatment?

The drug was a boon for many patients, mainly those with moderate to severe disease, but cost and insurance approvals posed challenges.

Q&A: Improved outcomes anticipated with dupilumab for children with EoE

Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.